ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2017
Selective retina therapy with automatic real-time feedback-controlled dosimetry for chronic central serous chorioretinopathy in Korean patients.
Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 39 citations in OpenAlex.
- Factors affecting resolution of subretinal fluid after selective retina therapy for central serous chorioretinopathy.Scientific reports · 2021Trial
- Evaluation of the Safety and Efficacy of Selective Retina Therapy Laser Treatment in Patients with Central Serous Chorioretinopathy.Korean journal of ophthalmology : KJO · 2021Trial
- Effects of Selective Retina Therapy on Central Serous Chorioretinopathy with Serous Pigment Epithelial Detachments.Journal of clinical medicine · 2026Article
- Selective Retina Therapy With Fundus Image-Based Titration in Central Serous Chorioretinopathy: Prospective Outcomes and Predictive Factors.Translational vision science & technology · 2026Article
- Selective retina therapy for central serous chorioretinopathy with focal choroidal excavation: a retrospective case series of six eyes.International journal of retina and vitreous · 2025Article
- Treatment of central serous chorioretinopathy: new options for an old disease.Eye (London, England) · 2025Review
- Use of a Fundus Image-Based Titration Strategy for Selective Retina Therapy for Central Serous Chorioretinopathy.Journal of clinical medicine · 2024Article
- Selective retina therapy with real-time feedback-controlled technology in central serous chorioretinopathy: a 24-month follow-up real-world prospective study.BMJ open ophthalmology · 2024Article
- Long-Term Multimodal Imaging Analysis of Selective Retina Therapy Laser Lesions.Life (Basel, Switzerland) · 2023Article
- Comparative Treatment Study on Macular Edema Secondary to Branch Retinal Vein Occlusion by Intravitreal Ranibizumab with and without Selective Retina Therapy.Life (Basel, Switzerland) · 2023Article
- Algorithms for optoacoustically controlled selective retina therapy (SRT).Photoacoustics · 2022Article
- Factors Predicting Response to Selective Retina Therapy in Patients with Chronic Central Serous Chorioretinopathy.Journal of clinical medicine · 2022Article
- Selective retina therapy and thermal stimulation of the retina: different regenerative properties - implications for AMD therapy.BMC ophthalmology · 2021Article
- The Effect of Selective Retina Therapy with Automatic Real-Time Feedback-Controlled Dosimetry for Chronic Central Serous Chorioretinopathy: A Randomized, Open-Label, Controlled Clinical Trial.Journal of clinical medicine · 2021Article
- Optical dosimeter for selective retinal therapy based on multi-port fiber-optic interferometry.Biomedical optics express · 2021Article
- Investigations on Retinal Pigment Epithelial Damage at Laser Irradiation in the Lower Microsecond Time Regime.Investigative ophthalmology & visual science · 2021Article
- The Role of Imaging in Planning Treatment for Central Serous Chorioretinopathy.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Subthreshold Nano-Second Laser Treatment and Age-Related Macular Degeneration.Journal of clinical medicine · 2021Review
- Retinal pigment epithelial responses based on the irradiation density of selective retina therapy.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2021Article
- Central Serous Chorioretinopathy: Treatment with Laser.Pharmaceuticals (Basel, Switzerland) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the safety and efficacy of selective retina therapy (SRT) with real-time feedback-controlled dosimetry (RFD) in the treatment of chronic central serous chorioretinopathy (CSC).
methodsIn this retrospective case series study, 50 eyes of 49 patients with chronic CSC demonstrating focal or diffuse foveal leakages on fundus fluorescein angiography (FFA) were included. Following evaluation of test spots at temporal arcades, SRT (wavelength 527 nm, pulse repetition rate 100 Hz, pulse energy ramp with maximal 15 pulses) with retinal spot diameter of 200 μm was applied to the areas of each leakage observed on fluorescein angiography. Changes in mean best corrected visual acuity (BCVA), maximum macular thickness (MMT), subretinal fluid (SRF) height, and subfoveal choroidal thickness (SCT) were evaluated at 1, 2 and 3 months after treatment. RFD was used for adjusting the pulse energy. Eyes received a mean of 21.1 ± 18.1 treatment spots with a range of energies between 50uJ and 200uJ per pulse.
resultsSubretinal fluid (SRF) was completely resolved in 74% (37/50 eyes) at month 3. Mean BCVA (LogMAR) was improved from 0.44 ± 0.29 at baseline to 0.37 ± 0.32 at month 3 (p = 0.001). MMT was decreased from 335.0 ± 99.8 μm at baseline to 236.4 ± 66.4 μm after 3 months (p < 0.001). SRF height was decreased from 168.0 ± 77.3 μm at baseline to 29.0 ± 57.3 μm after 3 months (p < 0.001). However, the changes in SCT were not statistically significant (p = 0.48).
conclusionsSRT treatment with RFD showed favorable visual and anatomical outcomes in patients with chronic CSC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.